Mounjaro vs Zepbound: Are They the Same Drug?

The short answer

Mounjaro and Zepbound are both tirzepatide, the dual GIP/GLP-1 receptor agonist developed by Eli Lilly. Same active ingredient, same factories, same dosing strengths, same injection pen design. The only meaningful differences are the brand name on the box and the FDA-approved indication printed on the label.

Mounjaro was approved first (May 2022) for type 2 diabetes management.

Zepbound was approved later (November 2023) for chronic weight management in adults with obesity or overweight with weight-related comorbidities.

Pharmacologically, taking 5 mg of Mounjaro and 5 mg of Zepbound is identical. The molecules are the same, the pharmacokinetics are the same, the side effects are the same, and the effects on weight and glucose are the same. Anyone telling you otherwise — including some patient-confusion-driven discussion online — is mistaken about the underlying chemistry.

Why two names for one drug?

The pattern of one molecule under two brand names with different indications is common in pharmaceuticals. Several reasons drive it:

Regulatory clarity. The FDA approves drugs for specific indications. A diabetes drug approved for T2D management has labeling, marketing, and prescribing focused on that use case. Approving the same drug for a different population (people with obesity, regardless of T2D status) involves a separate FDA submission, separate Phase 3 trials, and a separate label. Different name reduces confusion about which population is which.

Payer separation. Insurance coverage operates on indication-specific approvals. A plan may cover diabetes medications but exclude obesity medications (or have different cost-sharing tiers, prior authorization requirements, or coverage criteria for each). Distinct brand names allow payers to maintain distinct coverage policies.

Marketing positioning. The marketing message for a diabetes drug ("better glycemic control with cardiovascular benefits") is different from the marketing message for an obesity drug ("substantial weight loss with metabolic benefits"). Separate names allow targeted marketing without confusing either patient population.

The same pattern applies elsewhere in the GLP-1 class: semaglutide is sold as Ozempic (T2D), Wegovy (obesity), and Rybelsus (oral T2D) — three names for what is fundamentally the same molecule with different delivery formats and indications.

Dosing: identical between the two

Both Mounjaro and Zepbound are available in the same dose strengths:

• 2.5 mg (starting/titration dose)
• 5 mg
• 7.5 mg
• 10 mg
• 12.5 mg
• 15 mg (maximum dose)

Both are once-weekly subcutaneous injections. Both use the same injector pen design. Both follow the same dose-escalation schedule — typically starting at 2.5 mg, escalating monthly by 2.5 mg increments until reaching the target therapeutic dose or maximum tolerability.

For diabetes, Mounjaro typical maintenance doses are 5-15 mg depending on glycemic response. For obesity, Zepbound typical maintenance doses are 5-15 mg depending on weight-loss response and tolerability. The maintenance dose tends to be higher in obesity contexts (more often at 10 or 15 mg) because weight loss benefits continue to scale with dose at the high end, whereas glycemic benefits plateau earlier.

Practical differences that aren't pharmacological

Several non-pharmacological differences may matter for individual patients:

Insurance coverage and cost. This is often the biggest practical difference. A patient with T2D may have full coverage for Mounjaro but only partial or no coverage for Zepbound. A patient with obesity but no diabetes may have the reverse. Cost-sharing tiers, prior authorization requirements, and step-therapy protocols (where insurance requires trying other drugs first) often differ between the two brand names.

Pharmacy stocking and availability. During the 2023-2024 tirzepatide shortage, Mounjaro and Zepbound experienced overlapping but not identical supply patterns — a pharmacy might have one in stock but not the other.

Prescribing context. An endocrinologist managing diabetes will typically prescribe Mounjaro; an obesity-medicine physician will typically prescribe Zepbound. Switching prescribers may switch the brand name even when the underlying medication doesn't change.

Compounding and substitution rules. The compounded-tirzepatide ecosystem has been substantially affected by FDA decisions through 2024-2025. The rules and availability differ in nuanced ways between the indications.

Can you switch between Mounjaro and Zepbound?

Pharmacologically, switching is trivial — same molecule, same dose. A patient who has been on Mounjaro 10 mg for diabetes management and gains an obesity diagnosis can be switched to Zepbound 10 mg without any titration, dose adjustment, or transition concerns. Effects continue uninterrupted because nothing actually changed except the label.

Insurance switches can be more complicated. A plan may require a new prior authorization or step-therapy review when switching brand names even if the molecule is the same. Patients sometimes report having to "re-justify" the medication when their indication or clinical context changes.

If your insurance covers one but not the other, talk to your prescriber about whether the other indication or brand name might fit your clinical picture in a way that aligns with coverage. This is a documentation and billing question rather than a clinical one.

Why the confusion exists

The two-names-for-one-drug pattern confuses many patients for understandable reasons:

Most consumers learn about prescription drugs through brand names rather than generic names. Mounjaro, Zepbound, Ozempic, and Wegovy are widely advertised; tirzepatide and semaglutide as molecule names are far less recognizable. When patients hear "Mounjaro for diabetes" and "Zepbound for weight loss" in separate marketing campaigns, the natural inference is that they're separate drugs.

Healthcare communication also typically uses brand names. Patients told "I'm starting you on Mounjaro" don't usually hear "which is tirzepatide, a dual GIP/GLP-1 agonist also marketed as Zepbound for obesity."

And the pricing experience reinforces the confusion — different copays, different coverage decisions, different pharmacy stocking patterns make the two feel like distinct products even though the medication is identical.

Understanding that they're the same drug clarifies several practical questions:

• If you've tolerated one, you'll tolerate the other (same molecule)
• If you've responded well to one, the other will work the same way
• "Should I switch from Mounjaro to Zepbound to lose more weight?" — the answer is no; the drug is the same. You'd need to address dose, adherence, or supporting interventions (nutrition, resistance training) instead.